HiLo Clinical Trial Launch

On 22 September 2006 the HiLo trial will be launched in the UK across the National Cancer Research Network. HiLo is a large (400 patients) randomised trial of high versus low dose radioiodine, with or without rhTSH, in patients with differentiated thyroid cancer. The trial is funded by Cancer Research UK and is the only randomised study in thyroid cancer currently in progress in the UK. The trial will determine whether (a) using a low administered activity (1.1 GBq) is as effective in ablating thyroid remnants as a high activity (3.7 GBq), and (b) using rhTSH just before ablation is associated with a similar ablation success rate compared to patients who discontinue thyroid hormone. It will also examine side effects and long-term outcome, and undertake an economic evaluation.
All centres are invited to participate.

For further details of the launch and the trial please contact
Pablo Alvarez, telephone 020 7679 8018
Email:pa@ctc.ucl.ac.uk